Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Study to Evaluate the Effect of Uninterrupted Anticoagulants in Catheter Ablation Procedure for Non-valvular Atrial Fibrillation - Comparison between Rivaroxaban and Warfarin -

Next Previous
Trial Profile

Exploratory Study to Evaluate the Effect of Uninterrupted Anticoagulants in Catheter Ablation Procedure for Non-valvular Atrial Fibrillation - Comparison between Rivaroxaban and Warfarin -

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Cerebral infarction; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms ASCERTAIN Study

Most Recent Events

  • 02 Jan 2017 Status changed from active, no longer recruiting to completed according to the results presented at the 89th Annual Scientific Sessions of the American Heart Association.
  • 16 Nov 2016 Primary endpoint (The incidence of asymptomatic cerebral infarction caused by catheter ablation) has not been met,according to the results presented at the 89th Annual Scientific Sessions of the American Heart Association.
  • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top